Clinical Trial Update: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating TQB2102 for injection in non-small cell lung cancer with HER2 gene abnormalities is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TQB2102

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING